Whether the insurance reimbursement criteria for 'Zejula,' a PARP inhibitor, will include 'HRD-positive' is gaining attention.

Sources said that Takeda Pharmaceuticals Korea is negotiating the price with the National Health Insurance Service (NHIS) for the Poly ADP-ribose Polymerase (PARP) inhibitor, Zejula, which is used to treat ovarian cancer. The drug price negotiation is intended to expand reimbursement for the drug.

Zejula is currently reimbursed for use as maintenance therapy in patients with BRCA mutation ovarian cancer who have responded to first-line treatment with platinum-based chemotherapy. The company aims to add the condition of homologous recombination repair deficiency (